B16 melanoma tumor-associated antigen (B16 TAA)

B16 melanoma tumor-associated antigens (TAAs) are a group of proteins expressed by the B16 mouse melanoma cell line, which serves as a primary preclinical model for human melanoma research. These antigens primarily consist of melanocyte differentiation proteins, including gp100 (Pmel17), tyrosinase-related protein 1 (TRP-1), tyrosinase-related protein 2 (TRP-2), and tyrosinase, all of which are involved in the melanin biosynthetic pathway. In the context of cancer, these proteins are targeted by various immunotherapies, such as peptide-based vaccines, DNA vaccines, and adoptive T-cell transfers like the Pmel-1 system. Because these antigens are non-mutated self-proteins, they are often characterized by weak immunogenicity due to central and peripheral tolerance mechanisms. Therapeutic strategies frequently aim to break this tolerance using potent adjuvants or cytokine support, which can lead to autoimmune side effects such as vitiligo or ocular uveitis. The B16 model is particularly valued for evaluating the efficacy of novel checkpoint inhibitors and vaccine platforms against established tumors and for studying mechanisms of tumor immune evasion, such as the downregulation of MHC class I molecules.

Other names

B16 melanoma tumor-associated antigensB16 melanoma antigensB16-associated antigensMelanoma-associated antigens (B16)B16-F10 antigens

Induction of tumor-specific cytotoxic T lymphocyte (CTL) responses and antibody-mediated tumor cell lysis.